Jade Biosciences (JBIO) Cash from Financing Activities (2021 - 2026)

Jade Biosciences has reported Cash from Financing Activities for 6 years, with the latest figure at -$795000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 13.57% year-over-year to -$795000.0; the trailing twelve-month figure through Mar 2026 stood at $360.7 million (up 93.84% YoY), and the FY2025 full-year result was $360.8 million, up 1318.84% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$795000.0, down from $170.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $191.3 million in Q2 2025, with the low at -$795000.0 in Q1 2026.
• Historically, Cash from Financing Activities has averaged $45.7 million across 5 years, with a median of $463000.0 in 2023.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 473760.0% — and 2025, when it plunged 248.62%.
• Jade Biosciences' Cash from Financing Activities stood at $357000.0 in 2022, then grew by 29.69% to $463000.0 in 2023, then soared by 19770.41% to $92.0 million in 2024, then jumped by 84.96% to $170.2 million in 2025, then plunged by 100.47% to -$795000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$795000.0 (Q1 2026), $170.2 million (Q4 2025), and $191.3 million (Q2 2025), per Business Quant data.